Efficiency of rituximab in acquired hemophilia: report of two cases and review of literature

Acquired hemophilia due to an inhibitor of factor VIII is a rare clinical situation. Rituximab is now used in the treatment of acquired hemophilia. We report two cases of acquired hemophilia treated by rituximab with efficiency. Rituximab appears to be a first line immunosuppressive therapy in acqui...

Full description

Saved in:
Bibliographic Details
Published in:La revue de medecine interne 2007-12, Vol.28 (12), p.862-865
Main Authors: Millet, A, Decaux, O, Bareau, B, Guillet, B, Cazalets, C, Perlat, A, Jego, P, Grosbois, B
Format: Article
Language:fre
Subjects:
Adult
Aged
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Factor VIII - metabolism
Female
Hemophilia A - drug therapy
Humans
Immunologic Factors - therapeutic use
Rituximab
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acquired hemophilia due to an inhibitor of factor VIII is a rare clinical situation. Rituximab is now used in the treatment of acquired hemophilia. We report two cases of acquired hemophilia treated by rituximab with efficiency. Rituximab appears to be a first line immunosuppressive therapy in acquired hemophilia, especially in post-partum hemophilia.
ISSN:0248-8663
DOI:10.1016/j.revmed.2007.06.017